The acute effects of OPC-8212, a newly synthesized orally effective inotropic agent, were assessed clinically. Eleven patients with moderate congestive heart failure received a single mean dose of 6.5 mg/kg body weight of the drug. Eight hours after administration, the cardiac and stroke work indexes increased by 11% (p < 0.01) and 20% (p < 0.005), respectively, with concomitant decreases in the diastolic pulmonary artery (25%, p < 0.005) and right atrial pressures (33%, p < 0.01). There were no significant changes in blood pressure or heart rate.The contractile state of the left ventricle was also assessed by the shift of the Starling curve. To construct the function curve, lower body negative pressure was used to regulate the venous retur...
The hemodynamic and neurohumoral effects of cummulative intravenous doses of piroximone (MDL 19205),...
Acute and chronic hemodynamic and clinical responses to milrinone, a new oral inotrope-vasodilator a...
AbstractDuring the past 10 years, more than 80 orally active vasodilator and inotropic agents have b...
The acute effects of OPC-8212, a newly synthesized orally effective inotropic agent, were assessed c...
AbstractObjectives. We sought to determine the precise myocardial effects of OPC-18790 as demonstrat...
Left ventricular end-systolic pressure-volume analysis was employed to assess the inotropic effect o...
The hemodynamic effects of CI-914, a phosphodiesterase inhibitor, were studied in 12 patients with l...
Inotropic agents are administered to improve cardiac output and peripheral perfusion in patients wit...
To evaluate the potential benefit of MDL 17043, a new inotrope-vasodilator agent, in the short- and ...
OPC–18790 is a novel inotropic agent which works partially by inhibiting phosphodiesterase without a...
The haemodynamic effects of dobutamine were studied in I4 patients with chronic congestive cardiac f...
Inotropes have been fundamental to resuscitation of acute cardiogenic shock for decades. Heart failu...
Treatment with inotropic agents is one of the most controversial topics in heart failure. Initial en...
Treatment with inotropic agents is one of the most controversial topics in heart failure. Initial en...
Dopamine receptor stimulation causes vascular and neurohumoral responses that may be beneficial in p...
The hemodynamic and neurohumoral effects of cummulative intravenous doses of piroximone (MDL 19205),...
Acute and chronic hemodynamic and clinical responses to milrinone, a new oral inotrope-vasodilator a...
AbstractDuring the past 10 years, more than 80 orally active vasodilator and inotropic agents have b...
The acute effects of OPC-8212, a newly synthesized orally effective inotropic agent, were assessed c...
AbstractObjectives. We sought to determine the precise myocardial effects of OPC-18790 as demonstrat...
Left ventricular end-systolic pressure-volume analysis was employed to assess the inotropic effect o...
The hemodynamic effects of CI-914, a phosphodiesterase inhibitor, were studied in 12 patients with l...
Inotropic agents are administered to improve cardiac output and peripheral perfusion in patients wit...
To evaluate the potential benefit of MDL 17043, a new inotrope-vasodilator agent, in the short- and ...
OPC–18790 is a novel inotropic agent which works partially by inhibiting phosphodiesterase without a...
The haemodynamic effects of dobutamine were studied in I4 patients with chronic congestive cardiac f...
Inotropes have been fundamental to resuscitation of acute cardiogenic shock for decades. Heart failu...
Treatment with inotropic agents is one of the most controversial topics in heart failure. Initial en...
Treatment with inotropic agents is one of the most controversial topics in heart failure. Initial en...
Dopamine receptor stimulation causes vascular and neurohumoral responses that may be beneficial in p...
The hemodynamic and neurohumoral effects of cummulative intravenous doses of piroximone (MDL 19205),...
Acute and chronic hemodynamic and clinical responses to milrinone, a new oral inotrope-vasodilator a...
AbstractDuring the past 10 years, more than 80 orally active vasodilator and inotropic agents have b...